Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics Inc (NQ: AQST )

4.220 -0.510 (-10.78%)
Official Closing Price Updated: 7:59 PM EST, Mar 4, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aquestive Therapeutics Inc

< Previous 1 2 3 Next >
SHAREHOLDER ALERT: Robbins LLP Announces That Aquestive Therapeutics, Inc. (AQST) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of Aquestive Therapeutics, Inc. (NASDAQ: AQST) filed a class action complaint against the Company and its officers and directors for... 
From Business Wire News Releases
The Law Offices of Frank R. Cruz Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors
The Law Offices of Frank R. Cruz Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors 
From Business Wire News Releases
AQUESTIVE THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP notifies investors that a securities class action lawsuit has been filed in the United States District Court
LEAD PLAINTIFF DEADLINE IS APRIL 30, 2021 
From GlobeNewswire News Releases
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Conta
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. 
From Business Wire News Releases
Notice of Lead Plaintiff Deadline for Shareholders in the Aquestive Therapeutics, Inc. Class Action Lawsuit
The suit alleges defendants issued false statements concerning Aquestive business and prospects, resulting in its stock trading at inflated prices. 
From Business Wire News Releases
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - AQST
From PR Newswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Aquestive Therapeutics, Inc. (“Aquestive” or the... 
From Business Wire News Releases
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) investors concerning the Company’s possible violations... 
From Business Wire News Releases
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. 
From Business Wire News Releases
AQST INVESTOR LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf... 
From PR Newswire
AQST BREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline – AQST
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between... 
From Business Wire News Releases
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
From GlobeNewswire News Releases
AQST Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ:... 
From PR Newswire
AQST INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc.
From GlobeNewswire News Releases
Pomerantz Law Firm Announces the Filing of a Class Action against Aquestive Therapeutics, Inc. and Certain Officers - AQST
Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) and certain of its officers. The class action,... 
From PR Newswire
Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant™ (diazepam) Buccal Film Following FDA Feedback
From GlobeNewswire News Releases
Aquestive Therapeutics to Announce Fourth Quarter and Year End 2020 Financial Results and Recent Business Highlights on March 9 and Host Conference Call on March 10 at 8:00 a.m. ET
From GlobeNewswire News Releases
Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors
From GlobeNewswire News Releases
Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy
From GlobeNewswire News Releases
Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment
Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced a licensing and supply deal for the U.S. rights to commercialize EXSERVAN™ (riluzole), an... 
From PR Newswire
Aquestive Therapeutics Provides Business Update
From GlobeNewswire News Releases
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
From GlobeNewswire News Releases
Aquestive Therapeutics Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer
From GlobeNewswire News Releases
Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
From GlobeNewswire News Releases
Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization
Receives first milestone payment of $10 million, bringing total fourth quarter proceeds to $50 million 
From GlobeNewswire News Releases
Aquestive Therapeutics Completes FDA Type A Meeting on Libervant
From GlobeNewswire News Releases
Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125 Million
From GlobeNewswire News Releases
Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
From GlobeNewswire News Releases
Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters
From GlobeNewswire News Releases
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.